NCT02804776View on ClinicalTrials.gov

PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 27, 2015

Primary Completion Date

February 21, 2018

Study Completion Date

February 21, 2018

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Gefitinib

250mg oral daily for 4 weeks

Trial Locations (1)

169610

National Cancer Centre, Singapore

All Listed Sponsors
lead

National Cancer Centre, Singapore

OTHER

NCT02804776 - PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery | Biotech Hunter | Biotech Hunter